Senti Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(46,971) | $(52,180) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 4,281 | 1,150 |
| Depreciation | 2,744 | 2,901 |
| Change in fair value of GeneFab Note Receivable - related party | — | 17,240 |
| Change in fair value of GeneFab Economic Share - related party | — | 1,816 |
| Change in fair value of GeneFab Option - related party | — | (6,331) |
| Loss on sale of property and equipment - related party | — | 107 |
| Impairment of long-lived assets | — | 313 |
| Other non-cash charges | 39 | 7 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 12 | 38 |
| GeneFab receivable - related party | 49 | (132) |
| GeneFab prepaid expenses - related party | 4,573 | 10,915 |
| Prepaid expenses and other assets | 217 | 1,116 |
| Operating lease right-of-use assets | 1,687 | 1,491 |
| Accounts payable | 570 | (442) |
| Accrued expenses and other current liabilities | 308 | (2,702) |
| Operating lease liabilities | (3,418) | (2,963) |
| GeneFab sublease deferred income - related party | (660) | (350) |
| Other non-current liabilities | — | 113 |
| Net cash used in operating activities | (36,569) | (27,893) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchases of property and equipment | (196) | (15) |
| Proceeds from sale of property and equipment | 12 | 60 |
| Net cash provided by (used in) investing activities | (184) | 45 |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from CIRM Grant | 2,520 | 2,430 |
| Proceeds from issuance of common stock related to ATM, net of commissions | 670 | — |
| Payment of issuance costs | (2,469) | — |
| Proceeds from issuance of common stock under Common Stock Purchase Agreement | — | 10 |
| Net cash provided by financing activities | 721 | 2,440 |
| NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | (36,032) | (25,408) |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period | 51,815 | 39,448 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period | $15,783 | $14,040 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.